Association of neutrophil-to-lymphocyte ratio with clinical outcomes after percutaneous coronary intervention
- 1 October 2025
- journal article
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (5) , 669-678
Abstract
Aims: Inflammation contributes significantly to coronary artery disease (CAD). The neutrophil-to-lymphocyte ratio (NLR) has emerged as a readily available biomarker reflecting both inflammatory and immune cells’ activity, potentially enhancing risk stratification of patients with CAD. This study evaluates the clinical impact of baseline NLR in patients undergoing percutaneous coronary intervention (PCI) for both chronic coronary syndrome and acute coronary syndrome (ACS). Methods and results: We conducted a retrospective analysis of patients undergoing PCI at Mount Sinai Hospital between 2012 and 2022. Patients were stratified into NLR quartiles and outcomes were analysed using Cox regression models. The primary endpoint was major adverse cardiovascular events (MACEs) at 1-year follow-up, including all-cause death, myocardial infarction (MI), and stroke. A total of 7287 patients were included in the study. Age, male sex, comorbidities, high-sensitivity C-reactive protein, and complexity of PCI tended to be higher in the highest NLR quartiles. At 1 year, MACE incidence increased across NLR quartiles, from 5.1% (1st quartile) to 9.3% (4th quartile) (P for trend = 0.004). Compared with the 1st quartile, the 4th NLR quartile (NLR > 5.0) was associated with increased adjusted risks of MACE [adjusted hazard ratio (adjHR) 1.52, 95% CI 1.12–2.05], all-cause death (adjHR 1.71, 95% CI 1.10–2.65), MI (adjHR 1.53, 95% CI 1.00–2.35), and bleeding (adjHR 2.01, 95% CI 1.50–2.70). Ischaemic risk associated with high NLR was more pronounced in patients presenting with ACS and chronic kidney disease (CKD). Conclusion: Baseline NLR is associated with adverse cardiovascular outcomes in CAD patients undergoing PCI. Assessment of NLR could enhance risk stratification particularly in patients with ACS and CKD.Keywords
Funding Information
- German Heart Foundation (S/06/23)
- AngioWave
- Boehringer Ingelheim
- CellProthera
- Cereno Scientific
- High Enroll
- Level Ex
- McKinsey
- Medscape Cardiology
- NirvaMed
- PhaseBio
- PLx Pharma
- American Heart Association New York City
- AngioWave
- Broadview Ventures
- GlaxoSmithKline
- Hims
- SFJ
- Youngene;
- Acesion Pharma
- Assistance publique-Hôpitaux de Paris
- Baim Institute for Clinical Research
- Harvard Clinical Research Institute
- PORTICO
- PEITHO
- Cleveland Clinic
- Contego Medical
- Mayo Clinic
- Mount Sinai School of Medicine
- ENVISAGE
- ABILITY-DM
- ALLAY-HF
- Alleviant Medical
- Rutgers University
- NIH
- MINT
- American College of Cardiology
- Clinical Trials and News
- ACC Accreditation Oversight Committee
- Sanofi
- Bristol-Myers Squibb clopidogrel litigation
- Baim Institute for Clinical Research
- Harvard Clinical Research Institute
- RE-DUAL PCI
- Boehringer Ingelheim; AEGIS-II
- Belvoir Publications
- Harvard Heart Letter
- Canadian Medical and Surgical Knowledge Translation Research Group
- CSL Behring
- AHA lecture
- Cowen and Company
- Duke Clinical Research Institute
- PRONOUNCE
- HMP Global
- Journal of Invasive Cardiology
- Journal of the American College of Cardiology
- K2P
- Level Ex
- Medtelligence
- ReachMD
- MJH Life Sciences
- Oakstone CME
- Comprehensive Review of Interventional Cardiology
- Piper Sandler
- Population Health Research Institute
- COMPASS
- Bayer
- WebMD
- WILEY
- Clinical Cardiology
- Sotagliflozin
- Brigham and Women’s Hospital
- Abbott
- Acesion Pharma
- Afimmune
- Aker BioMarine
- Alnylam
- Amarin
- AstraZeneca
- Bayer
- Beren
- Boston Scientific
- Cardax
- CellProthera
- Cereno Scientific
- CinCor
- Cleerly
- CSL Behring
- Eisai
- Ethicon
- Faraday Pharmaceuticals
- Ferring Pharmaceuticals
- Forest Laboratories
- Fractyl
- Garmin
- HLS Therapeutics
- Ironwood
- Ischemix
- Janssen
- Javelin
- LEXICON
- Lilly
- Medtronic
- Merck
- Moderna
- MyoKardia
- NirvaMed
- Novartis
- Novo Nordisk
- Otsuka
- Owkin
- Pfizer
- PhaseBio
- PLx Pharma
- Recardio
- Regeneron
- Reid Hoffman Foundation
- Roche
- Sanofi
- Stasys
- Synaptic
- The Medicines Company
- Youngene
- 89bio
- Elsevier
- Abbott
- Biotronik
- CSI
- Endotronix
- St. Jude Medical
- Philips
- SpectraWAVE
- Svelte
- Vascular Solutions
- American College of Cardiology
- FlowCo
- Abbott
- Affluent Medical
- Alleviant Medical
- Amgen
- BAIM
- Beth Israel Deaconess Medical Center
- Boston Scientific
- Bristol-Myers Squibb
- CardiaWave
- Chiesi
- Concept Medical
- Daiichi Sankyo
- Duke
- Faraday
- Idorsia
- Janssen
- MedAlliance
- Medscape
- Mediasphere
- Medtelligence
- Novartis
- Pi-Cardia
- Protembis
- RM Global Bioaccess Fund Management
- Sanofi
- Affluent Medical
- Boehringer Ingelheim
- Chiesi USA
- Cordis
- Esperion Science
- Innovative BioPharma
- IQVIA
- Medscape
- WebMD Global
- PeerView Institute for Medical Education
- Radcliffe
- Elixir Medical
- STEL
- ControlRad
- SCAI
- Faculty Cardiovascular Research Foundation
- JAMA Cardiology
- ACC
This publication has 36 references indexed in Scilit:
- Inflammatory risk and clinical outcomes according to polyvascular atherosclerotic disease status in patients undergoing PCIClinical Research in Cardiology, 2024
- Neutrophil-lymphocyte ratio and clinical outcomes in 19,697 patients with atrial fibrillation: Analyses from ENGAGE AF- TIMI 48 trialInternational Journal of Cardiology, 2023
- Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte RatioJAMA Cardiology, 2022
- Race and outcomes after percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular ConsortiumAmerican Heart Journal, 2022
- Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trialEBioMedicine, 2022
- Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary SyndromeJAMA Cardiology, 2021
- Impact of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio on 5-Year Clinical Outcomes of Patients with Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary InterventionJournal of Cardiovascular Translational Research, 2018
- Pre-procedural neutrophil-to-lymphocyte ratio and long-term cardiac outcomes after percutaneous coronary intervention for stable coronary artery diseaseAtherosclerosis, 2017
- Relationship between low lymphocyte count and major cardiac events in patients with acute chest pain, a non-diagnostic electrocardiogram and normal troponin levelsAtherosclerosis, 2009
- Predictive value of elevated neutrophil–lymphocyte ratio on cardiac mortality in patients with stable coronary artery diseaseClinica Chimica Acta, 2008